This supports the view that the clinical differences seen between BoAA and Caucasian women are due to underlying genetic differences, with a higher rate of TP53 mutations and ERBB2 amplification in tumours from BoAA women compared to tumours from Caucasian women [12,13], whereas the opposite is true for the frequency of PTEN mutations [14]. The gene discussed is ERBB2; the disease is neoplasm.